Bortezomib in combination with pegylated liposomal doxorubicin and thalidomide is an effective steroid independent salvage regimen for patients with relapsed or refractory multiple myeloma: results of a phase II clinical trial.

Autor: Chanan-Khan, Asher1,2 (AUTHOR) asher.chanan-khan@roswellpark.org, Miller, Kena C.1 (AUTHOR), Musial, Laurie3 (AUTHOR), Padmanabhan, Swaminathan1 (AUTHOR), Yu, Jihnhee4 (AUTHOR), Ailawadhi, Sikander1 (AUTHOR), Sher, Taimur1 (AUTHOR), Mohr, Alice1 (AUTHOR), Bernstein, Zale P.1 (AUTHOR), Barcos, Maurice5 (AUTHOR), Patel, Mehul1 (AUTHOR), Iancu, Dan5 (AUTHOR), Lee, Kelvin1,6 (AUTHOR), Czuczman, Myron S.1 (AUTHOR)
Zdroj: Leukemia & Lymphoma. Jul2009, Vol. 50 Issue 7, p1096-1101. 6p. 3 Charts, 2 Graphs.
Databáze: Academic Search Ultimate
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje